Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:OKYO

OKYO Pharma 1/30/2026 Earnings Report

OKYO Pharma logo
$1.60 +0.01 (+0.63%)
Closing price 04:00 PM Eastern
Extended Trading
$1.61 +0.01 (+0.63%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

OKYO Pharma EPS Results

Actual EPS
-$2.28
Consensus EPS
-$0.07
Beat/Miss
Missed by -$2.21
One Year Ago EPS
N/A

OKYO Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OKYO Pharma Announcement Details

Quarter
Date
1/30/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

OKYO Pharma's next earnings date is estimated for Wednesday, June 3, 2026, based on past reporting schedules.

Conference Call Resources

OKYO Pharma Earnings Headlines

OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment
 |  finance.yahoo.comhttps://finance.yahoo.com/video/okyo-pharma-strengthens-scientific-advisory-150222598.html
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board
May 19 at 10:00 AM  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1092537?snapi
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.tc pixel
May 19 at 1:00 AM  |  American Alternative (Ad)
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
May 19 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/19/3297330/0/en/okyo-expands-scientific-advisory-board-with-the-appointment-of-international-expert-marta-sacchetti-md-phd.html
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3283612/0/en/okyo-ceo-and-cso-to-present-and-leadership-team-to-participate-at-upcoming-scientific-conferences-in-may.html
OKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026
April 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/okyo-pharma-advances-clinical-strategy-124000647.html?fr=sycsrp_catchall
See More OKYO Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OKYO Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OKYO Pharma and other key companies, straight to your email.

About OKYO Pharma

OKYO Pharma (NASDAQ:OKYO) Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease. The company’s second program, OK-202, is advancing in preclinical studies for chronic graft-versus-host disease, with plans to expand into other fibrotic indications. These programs leverage the company’s expertise in biologics engineering to deliver enhanced therapeutic profiles, including improved half-life and tissue targeting.

Founded through a combination of biotechnology collaborations and strategic financing, Okyo Pharma completed its initial public offering on the NASDAQ under the ticker symbol OKYO. Headquartered in the United States, the company has established research partnerships across North America and Europe to support its clinical development efforts. Leadership is headed by Chief Executive Officer Thomas Baum, Ph.D., who brings extensive experience in biologics development and regulatory strategy.

View OKYO Pharma Profile
Earnings Tools